OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Urinary p75ECD levels in patients with amyotrophic lateral sclerosis: a meta-analysis
Guanzhong Shi, Shuai Shao, Jinxia Zhou, et al.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2021) Vol. 23, Iss. 5-6, pp. 438-445
Closed Access | Times Cited: 12
Guanzhong Shi, Shuai Shao, Jinxia Zhou, et al.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (2021) Vol. 23, Iss. 5-6, pp. 438-445
Closed Access | Times Cited: 12
Showing 12 citing articles:
Unraveling the Heterogeneity of ALS—A Call to Redefine Patient Stratification for Better Outcomes in Clinical Trials
Laura Tzeplaeff, Alexandra V. Jürs, Camilla Wohnrade, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 452-452
Open Access | Times Cited: 8
Laura Tzeplaeff, Alexandra V. Jürs, Camilla Wohnrade, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 452-452
Open Access | Times Cited: 8
Diagnostic criteria for amyotrophic lateral sclerosis
Hannah C. Timmins, Alexandra E. Thompson, Matthew C. Kiernan
Current Opinion in Neurology (2024) Vol. 37, Iss. 5, pp. 570-576
Closed Access | Times Cited: 8
Hannah C. Timmins, Alexandra E. Thompson, Matthew C. Kiernan
Current Opinion in Neurology (2024) Vol. 37, Iss. 5, pp. 570-576
Closed Access | Times Cited: 8
Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis
Jared S. Katzeff, Fiona Bright, Katherine Phan, et al.
Brain (2022) Vol. 145, Iss. 5, pp. 1598-1609
Open Access | Times Cited: 33
Jared S. Katzeff, Fiona Bright, Katherine Phan, et al.
Brain (2022) Vol. 145, Iss. 5, pp. 1598-1609
Open Access | Times Cited: 33
Neurotrophic factors in the physiology of motor neurons and their role in the pathobiology and therapeutic approach to amyotrophic lateral sclerosis
Wesley M. Stansberry, Brian A. Pierchala
Frontiers in Molecular Neuroscience (2023) Vol. 16
Open Access | Times Cited: 10
Wesley M. Stansberry, Brian A. Pierchala
Frontiers in Molecular Neuroscience (2023) Vol. 16
Open Access | Times Cited: 10
Physical activities and risk of neurodegenerative diseases: A two-sample Mendelian randomization study
Qiao Liao, Jian He, Kun Huang
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 14
Qiao Liao, Jian He, Kun Huang
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 14
Biofluid Biomarkers in the Prognosis of Amyotrophic Lateral Sclerosis: Recent Developments and Therapeutic Applications
Daniel Sánchez‐Tejerina, Arnau Llauradó, J. Sotoca, et al.
Cells (2023) Vol. 12, Iss. 8, pp. 1180-1180
Open Access | Times Cited: 8
Daniel Sánchez‐Tejerina, Arnau Llauradó, J. Sotoca, et al.
Cells (2023) Vol. 12, Iss. 8, pp. 1180-1180
Open Access | Times Cited: 8
A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial
V Srinivasan, Victoria Homer, Darren Barton, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0291285-e0291285
Open Access | Times Cited: 1
V Srinivasan, Victoria Homer, Darren Barton, et al.
PLoS ONE (2024) Vol. 19, Iss. 7, pp. e0291285-e0291285
Open Access | Times Cited: 1
Trends in global amyotrophic lateral sclerosis research from 2000 to 2022: A bibliometric analysis
Guanzhong Shi, Jinxia Zhou, Kun Huang, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 6
Guanzhong Shi, Jinxia Zhou, Kun Huang, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 6
Pharmacological Treatments for Congenital Myasthenic Syndromes Caused by COLQ Mutations
Shuai Shao, Guanzhong Shi, Fangfang Bi, et al.
Current Neuropharmacology (2023) Vol. 21, Iss. 7, pp. 1594-1605
Open Access | Times Cited: 3
Shuai Shao, Guanzhong Shi, Fangfang Bi, et al.
Current Neuropharmacology (2023) Vol. 21, Iss. 7, pp. 1594-1605
Open Access | Times Cited: 3
Soluble p75 neurotrophic receptor as a reliable biomarker in neurodegenerative diseases: what is the evidence?
Georges Jourdi, Samuel Fleury, Imane Boukhatem, et al.
Neural Regeneration Research (2023) Vol. 19, Iss. 3, pp. 536-541
Open Access | Times Cited: 3
Georges Jourdi, Samuel Fleury, Imane Boukhatem, et al.
Neural Regeneration Research (2023) Vol. 19, Iss. 3, pp. 536-541
Open Access | Times Cited: 3
Clinical Correlates Identify ProBDNF and Thrombo-Inflammatory Markers as Key Predictors of Circulating p75NTR Extracellular Domain Levels in Older Adults
Samuel Fleury, Mireille E. Schnitzer, Lawrence Ledoux-Hutchinson, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 1
Samuel Fleury, Mireille E. Schnitzer, Lawrence Ledoux-Hutchinson, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 1
A low molecular weight dextran sulphate, ILB®, for the treatment of amyotrophic lateral sclerosis (ALS): an open-label, single-arm, single-centre, phase II trial
V Srinivasan, Victoria Homer, Darren Barton, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
V Srinivasan, Victoria Homer, Darren Barton, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
